Physician profile
Lauri S Blesch
NPI 1306896998
$2,259.70
in general payments reported to CMS, 2019-2025
19 companies · $285 in 2025
The $285 reported for 2025 was more than what 83% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $605 · 2020: $53.37 · 2021: $123 · 2022: $260 · 2023: $425 · 2024: $508 · 2025: $285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,218.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $603.93 | 2022-2025 | Azstarys |
| Glaxosmithkline, LLC. | $532.23 | 2019-2025 | Bexsero, Penmenvy, Shingrix |
| Novo Nordisk INC | $186.15 | 2019-2024 | |
| Pfizer INC. | $173.32 | 2019-2023 | |
| Ironshore Pharmaceuticals INC. | $156.33 | 2019 | |
| Amgen INC. | $125.19 | 2020-2024 | Repatha, Otezla |
| Lilly USA, LLC | $122.74 | 2019-2024 | Trulicity, Mounjaro, Zepbound |
| Dexcom, INC. | $77.49 | 2022-2025 | Dexcom G6 Transmitter |
| Supernus Pharmaceuticals, INC. | $68.38 | 2022-2023 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $48.87 | 2019-2023 | Trintellix |
| Abbott Laboratories | $29.50 | 2022-2024 | Freestyle Libre 3 |
| Tris Pharma INC | $23.57 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $19.13 | 2022 | |
| Avanir Pharmaceuticals, INC. | $18.52 | 2022 | |
| Xeris Pharmaceuticals, INC. | $16.44 | 2023 | Gvoke Hypopen |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $16.12 | 2025 | Jornay Pm |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.78 | 2024 | Xifaxan, Trulance |
| Axsome Therapeutics, INC. | $14.37 | 2024 | Auvelity |
| Merck Sharp & Dohme LLC | $11.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauri Blesch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.